

Advances in Experimental Medicine and Biology 1185

Catherine Bowes Rickman
Christian Grimm
Robert E. Anderson
John D. Ash
Matthew M. LaVail
Joe G. Hollyfield *Editors*

Retinal Degenerative Diseases

Mechanisms and Experimental Therapy

 Springer

Advances in Experimental Medicine and Biology

Volume 1185

Series Editors

Wim E. Crusio, *CNRS University of Bordeaux UMR 5287, Institut de
Neurosciences Cognitives et Intégratives d'Aquitaine, Pessac Cedex, France*

John D. Lambris, *University of Pennsylvania, Philadelphia, PA, USA*

Nima Rezaei, *Children's Medical Center Hospital, Tehran University
of Medical Sciences, Tehran, Iran*

More information about this series at <http://www.springer.com/series/5584>

Catherine Bowes Rickman
Christian Grimm
Robert E. Anderson • John D. Ash
Matthew M. LaVail • Joe G. Hollyfield
Editors

Retinal Degenerative Diseases

Mechanisms and Experimental
Therapy

 Springer

Editors

Catherine Bowes Rickman
Department of Ophthalmology
Duke University
Durham, NC, USA

Christian Grimm
Department of Ophthalmology
University Hospital Zurich
Zurich, Switzerland

Robert E. Anderson
Health Sciences Center
University of Oklahoma
Oklahoma City, OK, USA

John D. Ash
Ophthalmology
University of Florida
Gainesville, FL, USA

Matthew M. LaVail
Beckman Vision Center
University of California, San Francisco
San Francisco, CA, USA

Joe G. Hollyfield
Department of Ophthalmology
Case Western Reserve University
Cleveland, OH, USA

ISSN 0065-2598

ISSN 2214-8019 (electronic)

Advances in Experimental Medicine and Biology

ISBN 978-3-030-27377-4

ISBN 978-3-030-27378-1 (eBook)

<https://doi.org/10.1007/978-3-030-27378-1>

© Springer Nature Switzerland AG 2019, Corrected Publication 2020

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Preface

The International Symposia on Retinal Degeneration have been held in conjunction with the biennial meeting of the International Society for Eye Research (ISER) since 1984. These RD symposia have allowed basic and clinician scientists from around the world to convene and present their new research findings. They were organized to allow substantial time for discussions and one-on-one interactions in a relaxed atmosphere, where international friendships and collaborations could be fostered. The 18th International Symposium on Retinal Degeneration (also known as RD2018) was held from September 3 to 8, 2018, in the marvelous Victorian Hotel, The Great Southern, in the beautiful city of Killarney, Ireland. The meeting brought together 286 basic and clinician scientists, retinal specialists in ophthalmology, and trainees in the field from all parts of the world.

Abstract submissions to the RD2018 meeting exceeded all expectations, both in quantity and quality. The scientific program covered many aspects of retinal degeneration. The presentations included 44 platform talks and 153 posters. The program consisted of 3 full days of platform talks and 2 evening poster sessions. The RD2018 meeting was highlighted by four special keynote lectures. The first keynote lecture was given by *James Handa, MD*, Johns Hopkins University, who discussed “The RPE in AMD: Are They on an Inevitable Journey to Death?”. *Rando Allikmets, PhD*, of Columbia University gave the second keynote lecture titled “Solving Stargardt/ABCA4 Disease by Integrating Clinical and Genetic Analyses.” *Jacque Duncan, MD*, University of California at San Francisco, presented the third keynote lecture titled “Retinal Structure and Function in Patients with Retinal Degenerations.” The fourth and final keynote lecture was given by *Peter Humphries, PhD*, Trinity College Dublin, who discussed “On Experimental Approaches to Molecular Therapy for Retinal Degeneration.” The scientific meeting ended with a “Welcome to RD2020” by Local Organizer Juan Gallo, MD, along with the organizers primarily responsible for the meeting, Drs. John D. Ash and Eric Pierce.

We thank the Local Organizing Committee Chairs, *Dr. Peter and Marian Humphries*, Trinity College Dublin, and their Local Organizing Committee Members, Drs. *Laura Brady*, Fighting Blindness Ireland; *Matthew Campbell* and *Jane Farrar*, Trinity College Dublin; and *Paul Kenna*, Research Foundation, Royal Victoria Eye and Ear Hospital Dublin. In addition, we thank the outstanding management and staff of the Great Southern Hotel and Conference Center for their assistance in making this an exceptionally

smooth-running conference and a truly memorable experience for all of the attendees. These included, in particular, *Denise O'Sullivan* and *Aine McMahon*.

We were very pleased to be able to fund 65 “full-ride” travel awards for graduate students, postdocs, and junior faculty, the largest number of travel awards for an RD meeting to date! Travel awards were made possible in part by funding from the National Eye Institute (NEI) of the National Institutes of Health. We are pleased to report this is the ninth consecutive symposium in which the NEI has contributed travel awards to support young investigators. We are also grateful to the Foundation Fighting Blindness (FFB) for their continuous support since 1986. FFB, then known as the National Retinitis Pigmentosa Foundation, started supporting our meeting from our second meeting, RDII, and we dedicated our first volume (RDI) to Ben Berman who was the founder of FFB. Additional awards were provided by generous national and international financial support from a number of organizations, including the BrightFocus Foundation (since 2014), Pro Retina Germany (1998 and since 2012), the Fritz Tobler Foundation Switzerland (since 2012), Bayer, Novartis/Fighting Blindness Ireland, Science Foundation Ireland, Fáilte Ireland, and Biosciences Ireland. Many of the contributing foundations sent members of their organizations to attend the meeting. Their participation and comments in the scientific sessions were instructive to many, offering new perspectives to some of the problems being discussed.

We also acknowledge the diligent and outstanding efforts of Ms. *Holly Whiteside* and *Jazzamine Asberry*. Holly recently retired as the Administrative Manager of Dr. Anderson’s laboratory at the University of Oklahoma Health Sciences Center. She had been the RD Symposium Coordinator since 2000. Her duties were taken over for the RD2018 meeting by Jazzamine.

Finally, we acknowledge the contributions since 1984 of Matthew LaVail, one of the three founding organizers of the RD meetings. Matt has retired from the University of California at San Francisco and will no longer contribute (officially) to the ongoing RD meetings.

Catherine Bowes Rickman	Durham, NC, USA
Christian Grimm	Zurich, Switzerland
Robert E. Anderson	Oklahoma City, OK, USA
John D. Ash	Gainesville, FL, USA
Matthew M. LaVail	San Francisco, CA, USA
Joe G. Hollyfield	Cleveland, OH, USA

Contents

Part I Age-Related Macular Degeneration (AMD)

1 AMD-Associated HTRA1 Variants Do Not Influence TGF-β Signaling in Microglia	3
Isha Akhtar-Schaefer, Raphael Reuten, Manuel Koch, Markus Pietsch, and Thomas Langmann	
2 A Review of Pathogenic Drivers of Age-Related Macular Degeneration, Beyond Complement, with a Focus on Potential Endpoints for Testing Therapeutic Interventions in Preclinical Studies	9
Mayur Choudhary and Goldis Malek	
3 GPR143 Signaling and Retinal Degeneration	15
Anna G. Figueroa and Brian S. McKay	
4 Isolation of Retinal Exosome Biomarkers from Blood by Targeted Immunocapture	21
Mikael Klingeborn, Nikolai P. Skiba, W. Daniel Stamer, and Catherine Bowes Rickman	
5 Systemic Inflammatory Disease and AMD Comorbidity	27
Gloriane Schnabolk	
6 Adaptive and Maladaptive Complement Activation in the Retina	33
Sean M. Silverman and Wai T. Wong	
7 Long-Chain Polyunsaturated Fatty Acids and Age-Related Macular Degeneration	39
Dorota Skowronska-Krawczyk and Daniel L. Chao	
8 Melatonin as the Possible Link Between Age-Related Retinal Degeneration and the Disrupted Circadian Rhythm in Elderly	45
Nadezda A. Stepicheva, Joseph Weiss, Peng Shang, Meysam Yazdankhah, Sayan Ghosh, Imran A. Bhutto, Stacey Hose, J. Samuel Zigler Jr, and Debasish Sinha	

9	Active Cholesterol Efflux in the Retina and Retinal Pigment Epithelium	51
	Federica Storti and Christian Grimm	
10	Systematic Injection of Low-Dose LPS Transiently Improves the Retina Function and Structure of a Mouse Model of Geographic Atrophy	57
	Brianna M. Young and Cristhian J. Ildefonso	
Part II Gene Therapies		
11	Small Molecule-Based Inducible Gene Therapies for Retinal Degeneration	65
	Shyamtanu Datta, Hui Peng, and John D. Hulleman	
12	RNA-Based Therapeutic Strategies for Inherited Retinal Dystrophies	71
	Alejandro Garanto	
13	A Comparison of Inducible Gene Expression Platforms: Implications for Recombinant Adeno-Associated Virus (rAAV) Vector-Mediated Ocular Gene Therapy	79
	Daniel M. Lipinski	
14	Emerging Concepts for RNA Therapeutics for Inherited Retinal Disease	85
	Spencer M. Moore, Dorota Skowronska-Krawczyk, and Daniel L. Chao	
15	In Vivo Assessment of Potential Therapeutic Approaches for USH2A-Associated Diseases	91
	Nachiket D. Pendse, Veronica Lamas, Basil S. Pawlyk, Morgan L. Maeder, Zheng-Yi Chen, Eric A. Pierce, and Qin Liu	
16	Gene and Cell Therapy for AIPL1-Associated Leber Congenital Amaurosis: Challenges and Prospects	97
	Pedro R. L. Perdigo and Jacqueline van der Spuy	
17	Advancing Gene Therapy for PDE6A Retinitis Pigmentosa	103
	Simon M. Petersen-Jones, Laurence M. Occelli, Martin Biel, and Stylianos Michalakis	
18	Systemic Delivery of Genes to Retina Using Adeno-Associated Viruses	109
	Chiab P. Simpson, Susan N. Bolch, Ping Zhu, Frances Weidert, Astra Dinculescu, and Ekaterina S. Lobanova	
19	Progress in Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa	113
	Raghavi Sudharsan and William A. Beltran	

20	A Discovery with Potential to Revitalize Hammerhead Ribozyme Therapeutics for Treatment of Inherited Retinal Degenerations.	119
	Alexandria J. Trujillo, Jason M. Myers, Zahra S. Fayazi, Mark C. Butler, and Jack M. Sullivan	
21	Temporal Distribution Patterns of Alexa Fluor 647-Conjugated CeNPs in the Mouse Retina After a Single Intravitreal Injection	125
	Lily L. Wong, Swetha Barkam, Sudipta Seal, and James F. McGinnis	
Part III In-Vivo Imaging for Structure and Function		
22	Dysflective Cones.	133
	Jacque L. Duncan and Austin Roorda	
23	Multimodal Imaging in Choroideremia	139
	Katharina G. Foote, Austin Roorda, and Jacque L. Duncan	
24	Functional Assessment of Vision Restoration.	145
	Juliette E. McGregor, David R. Williams, and William H. Merigan	
25	Noninvasive Diagnosis of Regional Alteration of Retinal Morphology and Structure with Optical Coherence Tomography in Rodents.	151
	Fangfang Qiu, Meili Zhu, and Yun-Zheng Le	
Part IV Immunity and Inflammation		
26	Microglial Cell Dysfunction in <i>CRBI</i>-Associated Retinopathies.	159
	C. Henrique Alves and Jan Wijnholds	
27	Innate Immune Response Following AAV Administration	165
	D. L. Dauletbekov, J. K. Pfromm, A. K. Fritz, and M. D. Fischer	
28	The Role of Caveolin-1 in Retinal Inflammation	169
	Jami M. Gurley and Michael H. Elliott	
29	Increased Protein Citrullination as a Trigger for Resident Immune System Activation, Intraretinal Inflammation, and Promotion of Anti-retinal Autoimmunity: Intersecting Paths in Retinal Degenerations of Potential Therapeutic Relevance	175
	Alessandro Iannaccone and Marko Z. Radic	
30	Identification of a Unique Subretinal Microglia Type in Retinal Degeneration Using Single Cell RNA-Seq.	181
	Chen Yu and Daniel R. Saban	

Part V Inherited Retinal Degenerations

- 31 Description of Two Siblings with Apparently Severe *CEP290* Mutations and Unusually Mild Retinal Disease Unrelated to Basal Exon Skipping or Nonsense-Associated Altered Splicing** 189
Iris Barny, Isabelle Perrault, Marlène Rio, Hélène Dollfus, Sabine Defoort-Dhellemmes, Josseline Kaplan, Jean-Michel Rozet, and Xavier Gerard
- 32 Detection of Large Structural Variants Causing Inherited Retinal Diseases** 197
Stephen P. Daiger, Lori S. Sullivan, Sara J. Bowne, Elizabeth D. Cadena, Dan Koboldt, Kinga M. Bujakowska, and Eric A. Pierce
- 33 A Novel *FLVCR1* Variant Implicated in Retinitis Pigmentosa** 203
Adrian Dockery, Matthew Carrigan, Niamh Wynne, Kirk Stephenson, David Keegan, Paul F. Kenna, and G. Jane Farrar
- 34 Natural History and Genotype-Phenotype Correlations in *RDH12*-Associated Retinal Degeneration** 209
Abigail T. Fahim and Debra A. Thompson
- 35 Scaling New Heights in the Genetic Diagnosis of Inherited Retinal Dystrophies** 215
Roser González-Duarte, Marta de Castro-Miró, Miquel Tuson, Valeria Ramírez-Castañeda, Rebeca Valero Gils, and Gemma Marfany
- 36 Mutations in *VSX2*, *SOX2*, and *FOXE3* Identified in Patients with Micro-/Anophthalmia** 221
Imen Habibi, Mohamed Youssef, Eman Marzouk, Nihal El Shakankiri, Ghada Gawdat, Mohamed El Sada, Daniel F. Schorderet, and Hana Abou Zeid
- 37 Retinal Pigment Epithelial Cells: The Unveiled Component in the Etiology of Prpf Splicing Factor-Associated Retinitis Pigmentosa** 227
Abdallah Hamieh and Emeline F. Nandrot
- 38 Genetic Deciphering of Early-Onset and Severe Retinal Dystrophy Associated with Sensorineural Hearing Loss** 233
Sabrina Mechaussier, Sandrine Marlin, Josseline Kaplan, Jean-Michel Rozet, and Isabelle Perrault
- 39 Naturally Occurring Inherited Forms of Retinal Degeneration in Vertebrate Animal Species: A Comparative and Evolutionary Perspective** 239
Freya M. Mowat

40	RD Genes Associated with High Photoreceptor cGMP-Levels (Mini-Review)	245
	François Paquet-Durand, Valeria Marigo, and Per Ekström	
41	The Enigma of <i>CRB1</i> and <i>CRB1</i> Retinopathies	251
	Thomas A. Ray, Kelly J. Cochran, and Jeremy N. Kay	
42	Update on Inherited Retinal Disease in South Africa: Encouraging Diversity in Molecular Genetics	257
	Lisa Roberts, George Rebello, Jacquie Greenberg, and Raj Ramesar	
43	Emerging Drug Therapies for Inherited Retinal Dystrophies	263
	Husvinee Sundaramurthi, Ailís Moran, Andrea Cerquone Perpetuini, Alison Reynolds, and Breandán Kennedy	
44	Analysis of the <i>ABCA4</i> c.[2588G>C;5603A>T] Allele in the Australian Population	269
	Jennifer A. Thompson, John (Pei-Wen) Chiang, John N. De Roach, Terri L. McLaren, Fred K. Chen, Ling Hoffmann, Isabella Campbell, and Tina M. Lamey	
45	Retinal Bioenergetics: New Insights for Therapeutics	275
	Daniel M. Maloney, Naomi Chadderton, Arpad Palfi, Sophia Millington-Ward, and G. Jane Farrar	
46	Applications of Genomic Technologies in Retinal Degenerative Diseases	281
	Rinki Ratnapriya	
Part VI Mechanisms of Degeneration		
47	Lipid Signaling in Retinal Pigment Epithelium Cells Exposed to Inflammatory and Oxidative Stress Conditions. Molecular Mechanisms Underlying Degenerative Retinal Diseases	289
	Vicente Bermúdez, Paula E. Tenconi, Norma M. Giusto, and Melina V. Mateos	
48	Light Intensity-Dependent Dysregulation of Retinal Reference Genes	295
	Christina B. Bielmeier, Sabrina I. Schmitt, and Barbara M. Braunger	
49	cAMP and Photoreceptor Cell Death in Retinal Degeneration	301
	Jason Charish	
50	Pathomechanisms of ATF6-Associated Cone Photoreceptor Diseases	305
	Wei-Chieh Jerry Chiang, Heike Kroeger, Lulu Chea, and Jonathan H. Lin	

- 51 Differential Contribution of Calcium-Activated Proteases and ER-Stress in Three Mouse Models of Retinitis Pigmentosa Expressing P23H Mutant RHO** 311
Antonella Comitato, Davide Schirotti, Clara La Marca, and Valeria Marigo
- 52 Peroxisomal Disorders and Retinal Degeneration** 317
Yannick Das and Myriam Baes
- 53 Parthanatos as a Cell Death Pathway Underlying Retinal Disease** 323
Scott H. Greenwald and Eric A. Pierce
- 54 Inner Blood-Retinal Barrier Regulation in Retinopathies** 329
Natalie Hudson and Matthew Campbell
- 55 Oxidative Stress, Diabetic Retinopathy, and Superoxide Dismutase 3** 335
Larissa Ikelle, Muna I. Naash, and Muayyad R. Al-Ubaidi
- 56 Bisretinoids: More than Meets the Eye** 341
Hye Jin Kim and Janet R. Sparrow
- 57 Intravitreal Injection of Amyloid β 1–42 Activates the Complement System and Induces Retinal Inflammatory Responses and Malfunction in Mouse** 347
Ru Lin, Xinyu Fu, Chunyan Lei, Mingzhu Yang, Yiguo Qiu, and Bo Lei
- 58 Persistent Activation of STAT3 Pathway in the Retina Induced Vision Impairment and Retinal Degenerative Changes in Ageing Mice** 353
Bernadette Marrero, Chang He, Hyun-Mee Oh, Umegbewe T. Ukwu, Cheng-Rong Yu, Ivy M. Dambuza, Lin Sun, and Charles E. Egwuagu
- 59 High-Throughput Analysis of Retinal Cis-Regulatory Networks by Massively Parallel Reporter Assays** 359
Inez Y. Oh and Shiming Chen
- 60 Pathoconnectome Analysis of Müller Cells in Early Retinal Remodeling** 365
Rebecca L. Pfeiffer, James R. Anderson, Daniel P. Emrich, Jeebika Dahal, Crystal L. Sigulinsky, Hope A. B. Morrison, Jia-Hui Yang, Carl B. Watt, Kevin D. Rapp, Mineo Kondo, Hiroko Terasaki, Jessica C. Garcia, Robert E. Marc, and Bryan W. Jones

- 61 Sildenafil Administration in Dogs Heterozygous for a Functional Null Mutation in *Pde6a*: Suppressed Rod-Mediated ERG Responses and Apparent Retinal Outer Nuclear Layer Thinning 371**
Kenneth E. Pierce, Paul G. Curran, Christopher P. Zelinka, Andy J. Fischer, Simon M. Petersen-Jones, and Joshua T. Bartoe
- 62 Role of the *PNPLA2* Gene in the Regulation of Oxidative Stress Damage of RPE 377**
Preeti Subramanian and S. Patricia Becerra
- 63 HDAC Inhibition Prevents Primary Cone Degeneration Even After the Onset of Degeneration 383**
Marijana Samardzija, Klaudija Masarini, Marius Ueffing, and Dragana Trifunović
- 64 Live Imaging of Organelle Motility in RPE Flatmounts 389**
Ankita Umapathy and David S. Williams
- 65 ERG Alteration Due to the *rd8* Mutation of the *Crb1* Gene in *Cln3* *+/+* *rd8* *-/rd8*- Mice 395**
Cornelia Volz, Myriam Mirza, Thomas Langmann, and Herbert Jägle
- 66 Autophagy Induction by HDAC Inhibitors Is Unlikely to be the Mechanism of Efficacy in Prevention of Retinal Degeneration Caused by P23H Rhodopsin 401**
Runxia H. Wen, Aaron D. Loewen, Ruanne Y. J. Vent-Schmidt, and Orson L. Moritz
- 67 Techniques to Quantify cGMP Dysregulation as a Common Pathway Associated with Photoreceptor Cell Death in Retinitis Pigmentosa 407**
Paul Yang, Rachel A. Lockard, and Hope Titus
- 68 Hypoxia-Regulated MicroRNAs in the Retina 413**
Maya Barben, Ana Bordonhos, Marijana Samardzija, and Christian Grimm
- 69 Bestrophin1: A Gene that Causes Many Diseases 419**
Joseph J. Smith, Britta Nommiste, and Amanda-Jayne F. Carr
- 70 Analysis of Damage and Wound Healing in the Retinal Pigmented Epithelium 425**
K. J. Donaldson, W. F. Wu, H. Skelton, S. Markand, S. Ferdous, J. Sellers, M. A. Chrenek, I. Gefke, S. M. Kim, J. Rha, K. L. Liao, H. E. Grossniklaus, Y. Jiang, J. Kong, J. H. Boatright, and John M. Nickerson

71	Release of Retinal Extracellular Vesicles in a Model of Retinitis Pigmentosa	431
	Ayse Sahaboglu, Lorena Vidal-Gil, and Javier Sancho-Pelluz	
72	GSK-3 Inhibitors: From the Brain to the Retina and Back Again	437
	Alonso Sánchez-Cruz, Ana Martínez, Enrique J. de la Rosa, and Catalina Hernández-Sánchez	
Part VII Neuroprotection		
73	Signaling Mechanisms Involved in PEDF-Mediated Retinoprotection	445
	Glorivee Pagan-Mercado and S. Patricia Becerra	
74	Initial Assessment of Lactate as Mediator of Exercise-Induced Retinal Protection	451
	Jana T. Sellers, Micah A. Chrenek, Preston E. Girardot, John M. Nickerson, Machel T. Pardue, and Jeffrey H. Boatright	
75	The Resveratrol Prodrug JC19 Delays Retinal Degeneration in <i>rd10</i> Mice	457
	Lourdes Valdés-Sánchez, Ana B. García-Delgado, Adoración Montero-Sánchez, Berta de la Cerda, Ricardo Lucas, Pablo Peñalver, Juan C. Morales, Shom S. Bhattacharya, and Francisco J. Díaz-Corrales	
76	A Novel Mechanism of Sigma 1 Receptor Neuroprotection: Modulation of miR-214-3p	463
	Jing Wang and Sylvia B. Smith	
77	Critical Role of Trophic Factors in Protecting Müller Glia: Implications to Neuroprotection in Age-Related Macular Degeneration, Diabetic Retinopathy, and Anti-VEGF Therapies	469
	Bei Xu, Huiru Zhang, Meili Zhu, and Yun-Zheng Le	
Part VIII Retinal Cell Biology		
78	AMPK May Play an Important Role in the Retinal Metabolic Ecosystem	477
	Emily E. Brown, Alfred S. Lewin, and John D. Ash	
79	Prominin-1 and Photoreceptor Cadherin Localization in <i>Xenopus laevis</i>: Protein-Protein Relationships and Function	483
	Brittany J. Carr, Lee Ling Yang, and Orson L. Moritz	
80	Postmitotic Cone Migration Mechanisms in the Mammalian Retina	489
	Livia S. Carvalho and Carla B. Mellough	

81	The Role of the Prph2 C-Terminus in Outer Segment Morphogenesis	495
	Shannon M. Conley, Muayyad R. Al-Ubaidi, and Muna I. Naash	
82	The Dynamic and Complex Role of the Joubert Syndrome-Associated Ciliary Protein, ADP-Ribosylation Factor-Like GTPase 13B (ARL13B) in Photoreceptor Development and Maintenance	501
	Tanya Dilan and Visvanathan Ramamurthy	
83	No Difference Between Age-Matched Male and Female C57BL/6J Mice in Photopic and Scotopic Electroretinogram a- and b-Wave Amplitudes or in Peak Diurnal Outer Segment Phagocytosis by the Retinal Pigment Epithelium	507
	Francesca Mazzoni, Tasha Tombo, and Silvia C. Finnemann	
84	Mitochondrial Gymnastics in Retinal Cells: A Resilience Mechanism Against Oxidative Stress and Neurodegeneration	513
	Serena Mirra and Gemma Marfany	
85	New Insights into Endothelin Signaling and Its Diverse Roles in the Retina	519
	Sabrina I. Schmitt, Christina B. Bielmeier, and Barbara M. Braunger	
86	Analysis of ATP-Induced Ca²⁺ Responses at Single Cell Level in Retinal Pigment Epithelium Monolayers	525
	Juhana Sorvari, Taina Viheriälä, Tanja Ilmarinen, Teemu O. Ihalainen, and Soile Nymark	
87	PRCD Is a Small Disc-Specific Rhodopsin-Binding Protein of Unknown Function	531
	William J. Spencer and Vadim Y. Arshavsky	
88	RPE65 Palmitoylation: A Tale of Lipid Posttranslational Modification	537
	Sheetal Uppal, Eugenia Poliakov, Susan Gentleman, and T. Michael Redmond	
89	Studies of the Periciliary Membrane Complex in the Syrian Hamster Photoreceptor	543
	Junhuang Zou, Rong Li, Zhongde Wang, and Jun Yang	
Part IX Stem Cells		
90	Induction of Rod and Cone Photoreceptor-Specific Progenitors from Stem Cells	551
	Brian G. Ballios, Saeed Khalili, Molly S. Shoichet, and Derek van der Kooy	

**91 A Mini Review: Moving iPSC-Derived Retinal Subtypes
Forward for Clinical Applications for Retinal
Degenerative Diseases** 557
Chloe Cho, Thu T. Duong, and Jason A. Mills

92 Restoring Vision Using Stem Cells and Transplantation 563
Elisa Cuevas, Paresh Parmar, and Jane C. Sowden

**93 Subretinal Implantation of a Human Embryonic
Stem Cell-Derived Retinal Pigment Epithelium
Monolayer in a Porcine Model** 569
Amir H. Kashani, Ana Martynova, Michael Koss,
Rodrigo Brant, Dan Hong Zhu, Jane Lebkowski,
David Hinton, Dennis Clegg, and Mark S. Humayun

**94 Flavin Imbalance as an Important Player
in Diabetic Retinopathy** 575
Tirthankar Sinha, Muayyad R. Al-Ubaidi, and Muna I. Naash

Correction to: Retinal Degenerative Diseases C1

Index 581

Part I

Age-Related Macular Degeneration (AMD)



AMD-Associated HTRA1 Variants Do Not Influence TGF- β Signaling in Microglia

Isha Akhtar-Schaefer, Raphael Reuten,
Manuel Koch, Markus Pietsch,
and Thomas Langmann

Abstract

Genetic variants of high-temperature requirement A serine peptidase 1 (HTRA1) and age-related maculopathy susceptibility 2 (ARMS2) are associated with age-related macular degeneration (AMD). One HTRA1 single nucleotide polymorphism (SNP) is situated in the promoter region (rs11200638) resulting in increased expression, while two synonymous SNPs are located in exon 1 (rs1049331:C > T,

rs2293870:G > T). HtrA1 is known to inhibit transforming growth factor- β (TGF- β) signaling, a pathway regulating quiescence of microglia, the resident immune cells of the brain and retina. Microglia-mediated immune responses contribute to AMD pathogenesis. It is currently unclear whether AMD-associated HTRA1 variants influence TGF- β signaling and microglia phenotypes. Here, we show that an HtrA1 isoform carrying AMD-associated SNPs in exon 1 exhibits increased proteolytic activity. However, when incubating TGF- β -treated reactive microglia with HtrA1 protein variants, neither the wildtype nor the SNP-associated isoforms changed microglia activation in vitro.

I. Akhtar-Schaefer · T. Langmann (✉)
Laboratory for Experimental Immunology of the Eye,
Department of Ophthalmology, University of
Cologne, Faculty of Medicine and University
Hospital Cologne, Cologne, Germany
e-mail: thomas.langmann@uk-koeln.de

R. Reuten
Institute for Dental Research and Oral
Musculoskeletal Biology and Center for
Biochemistry, University of Cologne,
Cologne, Germany

Biotech Research and Innovation Centre (BRIC),
Faculty of Health and Medical Sciences, University
of Copenhagen, Copenhagen, Denmark

M. Koch
Institute for Dental Research and Oral
Musculoskeletal Biology and Center for
Biochemistry, University of Cologne,
Cologne, Germany

M. Pietsch
Institute II of Pharmacology, Center of
Pharmacology, Medical Faculty, University of
Cologne, Cologne, Germany

Keywords

Age-related macular degeneration (AMD) ·
Genome wide association studies (GWAS) ·
Single nucleotide polymorphisms (SNPs) ·
AMRS2/HTRA1 · Transforming growth
factor β (TGF- β) · TGF- β signaling ·
Microglia · Microglial quiescence ·
Immunomodulation

1.1 Introduction

Genome-wide association studies (GWAS) identified strong correlations between polymorphisms on chromosome 10q26 and AMD (Yang et al. 2006).

This locus harbors the genes for the HTRA1/ARMS2. The risk haplotype contains several SNPs, with one of which situated in the promoter region of HTRA1 (rs11200638), resulting in increased transcript and protein levels (Tuo et al. 2008). HtrA1 was found in drusen and the aqueous humor of AMD patients (Tosi et al. 2017). Mice overexpressing HtrA1 exhibited Bruch's membrane (BM) fragmentation which is characteristic for AMD (Vierkotten et al. 2011; Nakayama et al. 2014).

TGF- β is a well-defined regulator of immune regulation (Goumans et al. 2009). In the retina TGF- β belongs to factors released by the RPE into the sub-retinal space and exhibits immunosuppressive functions on the innate immune system by modulating microglia (Zamiri et al. 2007). Microglia, the resident immune cells in the retina, are responsible for tissue repair and pro-inflammatory responses associated with disease progression (Akhtar-Schaefer et al. 2018). TGF- β potently attenuates neuroinflammation by dampening microgliosis (Zöller et al. 2018). Whether HtrA1 contributes to inflammation by inhibiting TGF- β signaling remains largely elusive. An AMD-associated HtrA1 isoform, which carries two synonymous SNPs in exon 1 (rs1049331 and rs2293870), exhibited reduced binding to TGF- β in microglia (Friedrich et al. 2015). In the present study, we asked whether HtrA1 triggers pro-inflammatory microglia responses by interfering with TGF- β signaling.

1.2 Methods

1.2.1 Eukaryotic Protein Expression

The ORFs of wildtype (WT) and protease inactive (S328A) mouse (m) HtrA1 and WT, S328A, and AMD-associated (SNP) human (h) HtrA1 variants were cloned into an expression plasmid containing an N-terminal 2x Strep II tag. The S328A mutants contained a substitution of serine at position 328 with alanine, while the SNP isoform carried two SNPs in exon 1 (rs1049331:C > T: A34; rs2293870:G > T: G36). Proteins were expressed as previously described (Reuten et al. 2016).

1.2.2 Protease Assay

Enzymatic activity of HtrA1 was assessed using the EnzChek Protease Assay Kit (Thermo Fischer Scientific). HtrA1 proteins diluted in cold digestion buffer (10 mM Tris-HCL pH 7.8, 0.1 mM NaN₃) were pipetted into a black 96-well microtiter plate. Reaction was initiated by adding 5 μ g/ml BODIPY-FL casein. Increasing concentrations of HtrA1 were applied. The increase in relative fluorescence units (RFUs) at excitation/emission wavelengths of 485/535 nm was monitored every 20 seconds at 37 °C using an Infinite®F200 Pro plate reader (Tecan). Values were baseline corrected by subtracting the mean RFU increase without any enzyme.

1.2.3 Cell Culture

BV-2 microglia-like cells were cultured as previously described (Scholz et al. 2015). Cells were treated with 10 ng/ml interferon- γ (IFN- γ) or 1 ng/ml TGF- β (PreproTech) or both for 24 h. Treated cells were preincubated with 50 ng/ml, 100 ng/ml, and 150 ng/ml HtrA1 protein. For Smad2 expression analysis, cells were incubated with TGF- β and HtrA1 proteins for 3 h.

1.2.4 Quantitative Real-Time RT-PCR

RNA extraction and first-strand cDNA synthesis was performed as described previously (Madeira et al. 2018). Amplifications of 50 ng cDNA were performed with the LightCycler® 480 Instrument II (Roche). For the detection of plasminogen activator inhibitor 1 (Pai-1), iNos and arginase-1 (Arg1) intron spanning primers were used. ATP5B served as reference gene. The reactions were subjected to 40 cycles of amplification (95 °C for 15 s, 60 °C for 1 min). Relative quantification was performed using the LightCycler® 480 software 1.5.1.




Fig. 1.1 (a) Immunoblot of recombinant HtrA1 shows autolytic cleavage and smaller fragments which are absent in mS328A and hS328A (asterisk). (b) Slopes of enzymatic rates. Shown are mean values \pm SEM ($n = 3$)

1.2.5 Western Blot

Isolated proteins were subjected to Western blot analysis as previously described (Aslanidis et al. 2015). Primary antibodies against pSmad2 and Smad2 (Cell Signaling Technology) and secondary goat anti-rabbit IgG-HRP were used.

1.2.6 Statistical Analysis

Real-time RT-PCR data was analyzed using ANOVA followed by Tukey's multiple comparison test. pSmad2/Smad2 Western blot analysis data was analyzed using the non-parametric Kruskal-Wallis test, followed by Dunn's multiple comparison correction test using GraphPad Prism version 6.07. $P \leq 0.05$ which was considered as statistically significant.

1.3 Results

1.3.1 HtrA1 Protein Variants Are Proteolytically Active

We expressed recombinant mWT, mS328A, hWT, hSNP, and hS328A HtrA1. HtrA1 proteins were detected at approximately 59 kDa (Fig. 1.1a). Smaller fragments were partly attributed to autolytic cleavage. Quantitative protease assay using BODIPY FL-labeled casein demonstrated reproducible proteolytic activity of mWT, hWT, and hSNP forms (Fig. 1.1b).

1.3.2 HtrA1 Does Not Reduce TGF- β Induced Microglial Quiescence

Treatment of BV-2 cells with TGF- β led to a significant mRNA increase in its response gene Pai-1 (Fig. 1.2a). IFN- γ treatment induced a significant upregulation of iNos and reduction of the alternative activation marker Arg1 (Fig. 1.2d, g). TGF- β treatment reduced the pro-inflammatory phenotype of microglia by decreasing iNos and increasing Arg1 transcripts. When mWT was applied, we observed a significant decrease in Pai-1, Arg1, and iNos (Fig. 1.2b, e, h). However, when the human forms were applied, no significant changes were observed in transcript levels of any marker when compared to IFN- γ + TGF- β (Fig. 1.2c, f, i).

1.3.3 HtrA1 Protein Variants Do Not Change TGF- β Induced pSmad2 Levels

Smad2 proteins are phosphorylated upon TGF- β receptor activation. Hence, we evaluated the influence of HtrA1 variants on pSmad2 levels in TGF- β -treated BV-2 cells (Fig. 1.3). Application of 1 ng/ml TGF- β led to an increase in pSmad2 levels. However, co-treatment with any of the HtrA1 variants did not change pSmad2 levels.




Fig. 1.2 Treatment of BV-2 cells with TGF- β led to a significant increase in Pai-1 (a-c). Treatment with IFN- γ induced significant upregulation of iNos and reduction in Arg1. Co-treatment with TGF- β reduced the pro-inflammatory phenotype (d, g). Application of low-dose mWT led to a significant decrease in Pai-1 and Arg1 but also in iNos (b, e, h). Application of human HtrA1 led to no changes (c, f, i). Normalized values are presented as mean \pm SEM. ($n = 9$) with $***p \leq 0.001$




Fig. 1.3 HtrA1 does not change levels of pSmad2 after TGF- β stimulation. (a) Densitometric analysis of blots shown in (a) (b). Values are presented as mean \pm SEM. ($n = 6-14$) with $***p \leq 0.001$ when compared to TGF- β stimulation

1.4 Discussion

Here, we evaluated the effect of AMD-associated HtrA1 isoforms on microglia *in vitro*. First, all HtrA1 proteins, apart from the S328A forms, were proteolytically active. Interestingly, we observed increased catalytic activity of the proteins with the hSNP variant.

Second, we observed that TGF- β significantly inhibited IFN- γ -mediated iNos mRNA production, as previously described (Zöllner et al. 2018). However, we did not observe an influence of HtrA1 on microglial TGF- β signaling. Similar findings were reported with mucosal mast cells, where no inhibition of TGF- β signaling by HtrA1 was observed. (Gilicze et al. 2007)

Our results showed no differences between the wild-type and AMD-associated HtrA1 isoforms regarding TGF- β signaling. The synonymous AMD-associated SNPs are located in the insulin-like growth factor (IGF-1)-binding domain, and hSNP variants showed reduced ability to bind IGF-1 and TGF- β (Jacobco et al. 2013; Friedrich et al. 2015). However, these findings are challenged by our results. Further studies will have to address the question whether AMD-associated HtrA1 isoforms may influence retinal microglia *in vivo*.

References

- Akhtar-Schafer I, Wang L, Krohne TU et al (2018) Modulation of three key innate immune pathways for the most common retinal degenerative diseases. *EMBO Mol Med*
- Aslanidis A, Karlstetter M, Scholz R et al (2015) Activated microglia/macrophage whey acidic protein (AMWAP) inhibits NFkappaB signaling and induces a neuroprotective phenotype in microglia. *J Neuroinflammation* 12:77
- Friedrich U, Datta S, Schubert T et al (2015) Synonymous variants in HTRA1 implicated in AMD susceptibility impair its capacity to regulate TGF-beta signaling. *Hum Mol Genet* 24:6361
- Gilicze A, Kohalmi B, Pocza P et al (2007) HtrA1 is a novel mast cell serine protease of mice and men. *Mol Immunol* 44:2961–2968
- Goumans MJ, Liu Z, ten Dijke P (2009) TGF-beta signaling in vascular biology and dysfunction. *Cell Res* 19:116–127
- Jacobco SM, Deangelis MM, Kim IK et al (2013) Age-related macular degeneration-associated silent polymorphisms in HtrA1 impair its ability to antagonize insulin-like growth factor 1. *Mol Cell Biol* 33:1976–1990
- Madeira MH, Rashid K, Ambrosio AF et al (2018) Blockade of microglial adenosine A2A receptor impacts inflammatory mechanisms, reduces ARPE-19 cell dysfunction and prevents photoreceptor loss *in vitro*. *Sci Rep* 8:2272
- Nakayama M, Iejima D, Akahori M et al (2014) Overexpression of HtrA1 and exposure to mainstream cigarette smoke leads to choroidal neovascularization and subretinal deposits in aged mice. *Invest Ophthalmol Vis Sci* 55:6514–6523
- Reuten R, Nikodemus D, Oliveira MB et al (2016) Maltose-Binding Protein (MBP), a secretion-enhancing tag for mammalian protein expression systems. *PLoS One* 11:e0152386
- Scholz R, Sobotka M, Caramoy A et al (2015) Minocycline counter-regulates pro-inflammatory microglia responses in the retina and protects from degeneration. *J Neuroinflammation* 12:209
- Tosi GM, Caldi E, Neri G et al (2017) HTRA1 and TGF-beta1 concentrations in the aqueous humor of patients with neovascular age-related macular degeneration. *Invest Ophthalmol Vis Sci* 58:162–167
- Tuo J, Ross RJ, Reed GF et al (2008) The HtrA1 promoter polymorphism, smoking, and age-related macular degeneration in multiple case-control samples. *Ophthalmology* 115:1891–1898
- Vierkotten S, Muether PS, Fauser S (2011) Overexpression of HTRA1 leads to ultrastructural changes in the elastic layer of Bruch's membrane via cleavage of extracellular matrix components. *PLoS One* 6:e22959
- Yang Z, Camp NJ, Sun H et al (2006) A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. *Science (New York, NY)* 314:992–993
- Zamiri P, Sugita S, Streilein JW (2007) Immunosuppressive properties of the pigmented epithelial cells and the subretinal space. *Chem Immunol Allergy* 92:86–93
- Zöllner T, Schneider A, Kleimeyer C et al (2018) Silencing of TGF β signalling in microglia results in impaired homeostasis. *Nat Commun* 9:4011



A Review of Pathogenic Drivers of Age-Related Macular Degeneration, Beyond Complement, with a Focus on Potential Endpoints for Testing Therapeutic Interventions in Preclinical Studies

Mayur Choudhary and Goldis Malek

Abstract

Age-related macular degeneration (AMD) continues to be the leading cause of visual impairment for the elderly in developed countries. It is a complex, multifactorial, progressive disease with diverse molecular pathways regulating its pathogenesis. One of the cardinal features of the early clinical subtype of AMD is the accumulation of lipid- and protein-rich deposits within Bruch's membrane, called drusen, which can be visualized by fundus imaging. Currently, multiple *in vitro* and *in vivo* model systems exist, which can be used to help tease out mechanisms associated with different molecular pathways driving disease initiation and progression. Given the lack of treatments for patients suffering from the dry form of AMD, it is imperative to appreciate the differ-

ent known morphological endpoints associated with the various pathogenic pathways, in order to derive further insights, for the ultimate purpose of disease modeling and development of effective therapeutic interventions.

Keywords

Age-related macular degeneration · Lipid metabolism · Inflammation · Quick-freeze/deep etch · Retinal pigment epithelial cells · Cholesterol · Apolipoprotein

M. Choudhary
Department of Ophthalmology, Duke University
School of Medicine, Durham, NC, USA

G. Malek (✉)
Department of Ophthalmology, Duke University
School of Medicine, Durham, NC, USA

Department of Pathology, Duke University School of
Medicine, Durham, NC, USA

Albert Eye Research Institute, Durham, NC, USA
e-mail: gmalek@duke.edu

2.1 Introduction

Age-related macular degeneration (AMD) is a progressive and complex age-related disease. It is the leading cause of vision loss among people over 50 years of age in the Western world. Since the principle risk factor for AMD is advanced age, the number of people afflicted with AMD is estimated to rise to 288 million people by 2040 (Wong et al. 2014). A better understanding of the pathogenesis of AMD is crucial in identification and/or development of preclinical models, ultimately leading to effective therapeutics that may prevent or reverse this disease.

To date, several classification schemes of AMD have been described, based on in vivo imaging using color fundus photos and optical coherence tomography. The Age-Related Eye Disease Study (AREDS) is one of the most well-known systems of classification (Age-Related Eye Disease Study Research 2000). It classifies AMD into early, intermediate, and late stages. A major clinical feature of the disease is extracellular deposition of lipids and proteins underneath the retinal pigment epithelium (RPE) known as drusen. Early-stage “dry” AMD is characterized by the presence of medium-sized drusen ($>63\ \mu\text{m}$; $<125\ \mu\text{m}$) and pigmentary abnormalities; intermediate-stage “dry” AMD is defined by the presence of at least one large druse ($>125\ \mu\text{m}$) and numerous medium-sized drusen, or RPE atrophy excluding the macular region. Advanced-stage AMD can manifest in two forms that may coexist: (1) geographic atrophy (GA) or late “dry,” affecting 85–90% of patients, characterized by several large drusen and RPE atrophy extending to the center of the macula and (2) exudative AMD, affecting 10–15% of patients, defined by choroidal neovascularization and any of its associated sequelae such as subretinal fluid, hemorrhage, RPE detachment, and/or fibrotic scarring (Malek and Lad 2014). A subset of exudative AMD patients respond to antiangiogenic treatment targeting vascular endothelial growth factor (VEGF), whereas the quest for an effective therapy for GA remains elusive to date, due to its diverse and complex pathology, which involves multiple mechanisms including but not limited to dysregulation of lipid metabolism and transport, inflammation, complement pathway dysregulation, extracellular matrix (ECM) remodeling, cell death, and cell adhesion. The focus of this mini review is on the modeling of the pathobiology of dry AMD.

2.2 Pathobiology of AMD

The pathogenesis of AMD is influenced by cross talk between components of the retinal microenvironment, namely, photoreceptors, RPE cells, Bruch’s membrane (BrM), choriocapillaris, and

the outer choroid. Though complement has been shown to play an important part in regulating the health of the choriocapillaris as well as the RPE (Chirco et al. 2016), several other pathways have been shown to regulate the early stages of AMD including lipid metabolism and transport, inflammation, and ECM remodeling, whereas the late “dry” AMD seems to converge into pathogenic pathways such as cell senescence and death (Miller et al. 2017). Thus it would be valuable to develop a targeted approach to understanding modeling of disease phenotypes as well as identify quantifiable endpoints targeting these pathways.

2.2.1 Lipid Metabolic Dysregulation in AMD

One of the defining characteristics of early “dry” AMD is the accumulation of lipid-rich deposits between the RPE and BrM, as well as within BrM, which vary in size, thickness, and confluence (Klein et al. 1991). It has been shown that at least 40% of drusen volume is comprised of lipids (Wang et al. 2010). Components of drusen are derived from the retina, RPE, and to a lesser extent, the choroidal circulation. This retention of lipids causes formation of a variety of deposits, not only drusen but also basal laminar deposits (BLamD, between RPE and its plasma membrane) and basal linear deposits (BLinD, between the RPE and inner collagenous layer of BrM) (Curcio et al. 2011). Furthermore, genome-wide association studies (GWAS) of AMD patients have led to the identification of multiple lipid metabolism-related genes like *ABCA1*, *ABCA4*, *APOE*, *CETP*, and *LIPC* (Yu et al. 2011; Merle et al. 2013). Complementary to the GWAS reports, several epidemiological studies that have investigated the role of statins and AMD, point toward an association between circulating lipid levels and drusen formation (Klein et al. 2014; Vavvas et al. 2016). Possible mechanisms of statin therapy have been postulated, including changes in lipoprotein metabolism, improvement in lipid efflux, lipid clearing by macrophages, and anti-inflammatory and protective effects on

RPE cells. Collectively, these studies suggest that AMD may be reversible anatomically and functionally, and establishes lipid metabolism and transport as a viable target for disease modeling and therapy development.

Key players in cholesterol transport and lipid metabolism are apolipoproteins (apo), proteins that have been shown to accumulate in drusen. Accordingly, multiple studies have been conducted to date investigating the role of apolipoproteins using *in vivo* modeling, often incorporating an additional stressor such as dietary manipulation. For example, *apo*E3*-Leiden mice (modeling human type III hyperlipoproteinemia) when fed a high-fat diet for 9 months developed BLamD, composed of electron dense material similar to that seen in human AMD and immunoreactivity toward apoE, supporting apoE's involvement in BLamD development (Kliffen et al. 2000). Further, aged mice expressing the human *APOE4* allele maintained on a high cholesterol diet developed AMD-like pathology, including diffuse sub-RPE deposits, thickened BrM, and RPE atrophy (Malek et al. 2005). The apolipoprotein (apo) A-I mimetic peptide 4F, a small anti-inflammatory and anti-atherogenic agent, when delivered via intravitreal route in *apoE^{null}* mice displayed improvement in BrM's health and lessened the esterified cholesterol levels in BrM (Rudolf et al. 2018). Since apoB lipoprotein particles have been detected in BrM in early-stage "dry" AMD, transgenic mice expressing human apoB100 have been generated. High-fat diet and photooxidative injury in these transgenic mice resulted in loss of basal infoldings and cytoplasmic vacuoles in the RPE, in addition to accumulation of BLamD and long-spacing collagen in BrM (Espinosa-Heidmann et al. 2004; Fujihara et al. 2009). Additionally mice expressing mouse apoB100 develop lipoprotein accumulations in their BrM (Fujihara et al. 2014). These studies are consistent with the hypothesis that under conditions of hyperlipidemia, the RPE may secrete apoB100-rich lipoproteins to counter lipotoxicity, which may lead to the formation of lipid-rich deposits as seen in early-stage "dry" AMD. This may explain the aging effect, which in combination with photooxidative injury, leads to lipid accumulation, cul-

minating in the formation of sub-RPE deposits. The accumulation of drusen can be exacerbated by inflammation, as discussed in the next section.

2.2.2 Inflammation in AMD

Inflammation and immune dysfunction are other pathogenic mechanisms associated with AMD development and central to early stages of the disease. With aging, the retina suffers from a low-grade chronic oxidative insult, which it reportedly sustains for decades. Therefore, the inflammation/"para-inflammation" may at a given point cross a threshold, become pathogenic, and lead to disease development. Noteworthy is that human histological/biochemical evaluation of para-inflammation in the AMD eye is limited to studies that have shown involvement of CD163⁺, CD68⁺ and complement factor-3⁺ cells in AMD specimens (Lad et al. 2015; Wang et al. 2015; Natoli et al. 2017). In light of the "para-inflammation" hypothesis, the potential for modulating the inflammatory response is currently being evaluated as a therapeutic avenue in AMD.

An element of inflammation that has been postulated to regulate AMD pathogenesis is the NACHT, LRR, and PYD domains containing protein 3 (NLRP3) inflammasome. It is a large multiprotein complex within the immune cells that functions in the innate immune response pathway as a molecular platform for activation of caspase-1 and subsequent maturation and secretion of biologically active interleukin-1 β (IL-1 β) and IL-18 (Schroder and Tschopp 2010). Terallo et al. described that accumulation of Alu RNA transcripts in RPE following DICER1 loss primed and activated the NLRP3 inflammasome in RPE, leading to IL-1 β - and IL-18-mediated RPE degeneration (Tarallo et al. 2012).

2.3 Potential Endpoints for Preclinical Studies

This mini review has attempted to present some aspects of dry AMD pathobiology, with a focus on the role of lipid metabolism and inflammation

in the progression of the disease. Transgenic mouse models are an effective tool to study the contribution of specific molecular pathways to the pathogenicity of AMD. Targeting molecular pathways necessitates the use of unambiguous endpoints to elucidate the role of a particular pathway. For example, characterization of lipids present in mouse BrM requires staining reagents to establish the normal baseline, which then may be compared against genetic or dietary manipulations. Oil red O is a histological tool that may be employed to stain a class of lipids called neutral lipids which encompasses triglycerides (TG), esterified cholesterol (EC), and fatty acids (FA). Furthermore, EC and unesterified cholesterol (UC) can be distinguished by a fluorescent, polyene antibiotic filipin stain. Successful filipin staining has been shown in human tissue sections and cultured cells (Curcio et al. 2011). Ultrastructural studies using transmission electron microscopy (TEM) have long been a benchmark to study deposits in human tissue and animal models. It provides detailed visualization of photoreceptor outer segments, RPE cells and BrM. Using TEM, studies have illustrated electron dense materials below the RPE, RPE pigmented changes, BrM thickening, and changes in the choriocapillaris. Detailed views of ocular lipoprotein particles and ECM changes have also been made possible by quick-freeze/deep etch, a tissue preparation technique used in conjunction with electron microscopy that can produce three-dimensional images of tissue structure and macromolecular elements while preventing the introduction of post-processing artifacts (Ismail et al. 2017). Finally, immunohistochemical stains may be used to visualize lipid accumulations using antibodies against apoB, apoE, perilipin, and E06, which bind to proteins covalently modified by oxidized phospholipids (Malek et al. 2003; Harris et al. 2013).

Assessment of inflammation is also important as an *in vitro*, *ex vivo*, or *in vivo* endpoint and may be performed by surveying for immune cells. Retinal and RPE-choroid flatmounts are an excellent way to get an overview of the resident microglial cells to establish a baseline. The number and density of microglia can be used to evaluate the

effect of injury/insult or transgene expression. Various antibodies can be employed for this purpose, namely, Iba1 (ionized calcium-binding adaptor molecule 1), F4/80, CD68, and CD45. In addition to the number/density of immune cells, the morphological characterization of microglia/macrophage may be used as a measure of inflammatory status. Macrophages can differentiate into either classically activated M1 phenotype, characterized by the expression and production of pro-inflammatory mediators including IL-1 β , TNF- α , and IL-6 as well as an increased expression of surface markers such as CD16/32, CD86, CD40, and inducible nitric oxide synthase, which have been reported to drive the inflammatory process. Additionally, the M2 macrophages express high levels of arginase-1 and IL-10 but low levels of IL-12 and IL-23 and are usually induced by anti-inflammatory cytokines IL-4 and IL-13.

2.4 Summary

Investigation into the pathological mechanisms of a complex and multifactorial disease such as AMD may entail the use of an assortment of model systems, each of which may target distinct disease-associated pathways. It is imperative to develop a comprehensive understanding of potential endpoints associated with each model system in order to delve deeper into mechanistic questions as well as develop effective therapeutic modalities.

Acknowledgments This study was supported by NEI grants: R01EY027802 (GM), R01EY028160 (GM), and EY005722 (Duke Eye Center) and Research to Prevent Blindness core grant (Duke Eye Center).

References

- Age-Related Eye Disease Study Research G (2000) Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. *Ophthalmology* 107:2224–2232
- Chirco KR, Tucker BA, Stone EM et al (2016) Selective accumulation of the complement membrane attack complex in aging choriocapillaris. *Exp Eye Res* 146:393–397

- Curcio CA, Johnson M, Rudolf M et al (2011) The oil spill in ageing Bruch membrane. *Br J Ophthalmol* 95:1638–1645
- Espinosa-Heidmann DG, Sall J, Hernandez EP et al (2004) Basal laminar deposit formation in APO B100 transgenic mice: complex interactions between dietary fat, blue light, and vitamin E. *Invest Ophthalmol Vis Sci* 45:260–266
- Fujihara M, Bartels E, Nielsen LB et al (2009) A human apoB100 transgenic mouse expresses human apoB100 in the RPE and develops features of early AMD. *Exp Eye Res* 88:1115–1123
- Fujihara M, Cano M, Handa JT (2014) Mice that produce ApoB100 lipoproteins in the RPE do not develop drusen yet are still a valuable experimental system. *Invest Ophthalmol Vis Sci* 55:7285–7295
- Harris LA, Skinner JR, Wolins NE (2013) Imaging of neutral lipids and neutral lipid associated proteins. *Methods Cell Biol* 116:213–226
- Ismail EN, Ruberti JW, Malek G (2017) Quick-freeze/deep-etch electron microscopy visualization of the mouse posterior pole. *Exp Eye Res* 162:62–72
- Klein R, Davis MD, Magli YL et al (1991) The Wisconsin age-related maculopathy grading system. *Ophthalmology* 98:1128–1134
- Klein R, Myers CE, Buitendijk GH et al (2014) Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration consortium. *Am J Ophthalmol* 158:513–524 e513
- Kliffen M, Lutgens E, Daemen MJ et al (2000) The APO(*E3-Leiden mouse as an animal model for basal laminar deposit. *Br J Ophthalmol* 84:1415–1419
- Lad EM, Cousins SW, Van Arnem JS et al (2015) Abundance of infiltrating CD163+ cells in the retina of postmortem eyes with dry and neovascular age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 253:1941–1945
- Malek G, Lad EM (2014) Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration. *Cell Mol Life Sci* 71:4617–4636
- Malek G, Li CM, Guidry C et al (2003) Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. *Am J Pathol* 162:413–425
- Malek G, Johnson LV, Mace BE et al (2005) Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. *Proc Natl Acad Sci U S A* 102:11900–11905
- Merle BM, Maubaret C, Korobelnik JF et al (2013) Association of HDL-related loci with age-related macular degeneration and plasma lutein and zeaxanthin: the Alienor study. *PLoS One* 8:e79848
- Miller JW, Bagheri S, Vavvas DG (2017) Advances in age-related macular degeneration understanding and therapy. *US Ophthalmic Rev* 10:119–130
- Natoli R, Fernando N, Jiao H et al (2017) Retinal macrophages synthesize C3 and activate complement in AMD and in models of focal retinal degeneration. *Invest Ophthalmol Vis Sci* 58:2977–2990
- Rudolf M, Mir Mohi Sefat A, Miura Y et al (2018) ApoA-I Mimetic Peptide 4F reduces age-related lipid deposition in Murine Bruch's membrane and causes its structural remodeling. *Curr Eye Res* 43:135–146
- Schroder K, Tschopp J (2010) The inflammasomes. *Cell* 140:821–832
- Tarallo V, Hirano Y, Gelfand BD et al (2012) DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. *Cell* 149:847–859
- Vavvas DG, Daniels AB, Kapsala ZG et al (2016) Regression of some high-risk features of Age-related Macular Degeneration (AMD) in patients receiving intensive statin treatment. *EBioMedicine* 5:198–203
- Wang L, Clark ME, Crossman DK et al (2010) Abundant lipid and protein components of drusen. *PLoS One* 5:e10329
- Wang JC, Cao S, Wang A et al (2015) CFH Y402H polymorphism is associated with elevated vitreal GM-CSF and choroidal macrophages in the postmortem human eye. *Mol Vis* 21:264–272
- Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *Lancet Glob Health* 2:e106–e116
- Yu Y, Reynolds R, Fagerness J et al (2011) Association of variants in the LIPC and ABCA1 genes with intermediate and large drusen and advanced age-related macular degeneration. *Invest Ophthalmol Vis Sci* 52:4663–4670



GPR143 Signaling and Retinal Degeneration

3

Anna G. Figueroa and Brian S. McKay

Abstract

Age-related macular degeneration (AMD) is the most common cause of irreversible blindness. We do not know the cause of the disease and have inadequate prevention and treatment strategies for those at risk or affected. The greatest risk factors include age and race, with the white population at the highest risk for the disease. We developed the hypothesis that pigmentation in the retinal pigment epithelium (RPE) protects darkly pigmented individuals from AMD. We have tested this hypothesis in multiple ways including dissecting the pigmentation pathway in RPE using albinism-related tools, identification of a G protein-coupled receptor in the pigmentation pathway that drives expression of trophic factors, and using a very large retrospective chart analysis to test whether the ligand for the receptor prevents AMD. In total, our results indicate that pigmentation of the RPE is a cornerstone of RPE-retinal interaction and support and that the receptor in the pigmentation pathway most likely underlies the racial bias of the disease. The ligand for that receptor is an ideal candidate as a preventative and treatment for AMD. Here we summarize these

results, discussing the research in its entirety with one overall goal, treatment or prevention of AMD.

Keywords

AMD · Albinism · Retinal degeneration · Pigmentation · GPCR · GPR143 · OA1 · Dopamine · L-dopa · PEDF

3.1 Introduction

Age-related macular degeneration (AMD) is the most common cause of irreversible visual loss in the developed world, reviewed in (Jager et al. 2008). Despite years of intensive research, the pathogenesis and etiology of AMD are unknown. Some of the identified risk factors for AMD include genetics, age, gender, smoking, sunlight exposure, and race (Ehrlich et al. 2008). AMD is not a genetic disease, but clear association with various risk alleles within the complement system is strongly supported (Hageman et al. 2005; Loane et al. 2011; Holliday et al. 2013; Cascella et al. 2014). The immune system participates in the pathologic process of AMD, but whether that is a response to tissue injury or a primary cause of the disease remains unclear.

Race is one of the strongest risk factors for AMD, with the white population particularly susceptible (Fig. 3.1a). Race is a complex trait based

A. G. Figueroa · B. S. McKay (✉)
Department of Ophthalmology and Vision Science,
University of Arizona, Tucson, AZ, USA
e-mail: bsmckay@eyes.arizona.edu




Fig. 3.1 (a) Percentage of individuals with intermediate and advanced age-related macular degeneration separated by age and race. Adapted from the National Eye Institute (b) Overview of melanin synthesis compared to neuronal

dopamine synthesis. Both melanin and dopamine are derived from tyrosine, with an intermediate production of L-dopa

on many genes, but retinal pigment epithelium (RPE) pigmentation may be a key factor for the racial bias of AMD. Lessons from albinism, the loss of pigmentation, illustrate how RPE pigmentation supports the neurosensory retina. All forms of albinism are genetic, and all exhibit the same retinal phenotype, reviewed in (McKay 2018). Albinism from any cause, be it a lysosomal storage defect, enzymatic dysfunction in melanin synthesis, or loss of a G-protein-coupled receptor (GPCR), each causes a similar retinal phenotype. People with albinism frequently exhibit low vision due to developmental changes in the neurosensory retina, despite the fact that the retina never expresses any of the genes that cause albinism. The degree of visual problems varies among affected individuals, generally along with the residual levels of RPE pigmentation. Finally, the retinal consequences of albinism are the same in all races directly indicating that the relationship between RPE pigmentation and retinal support transcends the other genetic traits involved in race. AMD's prevalence is complex, as it appears to be equally distributed among all racial groups between the ages of 50–74 but becomes significantly greater in the white population after the age of 75 (Fig. 3.1a). Despite this finding and a linkage between RPE pigmentation and retinal health as suggested by the albinism retinal deficits, the contribution of pigment pathways to AMD remains to be elucidated.

3.2 GPR143 Biology

An important gene involved in the pigmentation pathway encodes a GPCR that is expressed in RPE and melanocytes, GPR143 (Schiaffino 2010). Genetic mutations in the gene encoding GPR143 cause ocular albinism which is associated with the complete retinal albinism phenotype—despite normal or near normal pigmentation in the RPE (Oetting 2002). This observation separates RPE pigmentation from the retinal albinism phenotype, because in individuals with mutations in GPR143, the RPE exhibits normal pigmentation but still develops retinal problems. This directly indicates that the retinal albinism phenotype is linked to GPR143, rather than RPE pigmentation. Further, the ocular albinism phenotype can be rescued by tyrosine hydroxylase activity; tyrosine hydroxylase produces L-dopa but not melanin (Lavado et al. 2006).

We discovered that a ligand for GPR143 is L-dopa, an intermediate product in melanin synthesis produced by the enzyme tyrosinase (Lopez et al. 2008). L-dopa is synthesized by tyrosinase activity and crosses membranes using the same transporter as tyrosine. Thus, L-dopa produced by tyrosinase in pigment granules is released into the RPE cytoplasm and subsequently accumulates in the subretinal space (Roffler-Tarlov et al. 2013). Tyrosinase catalyzes several steps through which tyrosine is hydroxylated creating L-dopa,